Comparison 9. Lenalidomide maintenance versus observation after debulking therapy.

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
9.1 Common adverse effects	1		Risk Ratio (M‐H, Fixed, 95% CI)	Totals not selected
9.1.1 Neutropenia	1		Risk Ratio (M‐H, Fixed, 95% CI)	Totals not selected
9.1.2 Hyperbilirubinaemia	1		Risk Ratio (M‐H, Fixed, 95% CI)	Totals not selected
9.1.3 Hypercalcaemia	1		Risk Ratio (M‐H, Fixed, 95% CI)	Totals not selected
9.1.4 Hypokalaemia	1		Risk Ratio (M‐H, Fixed, 95% CI)	Totals not selected
9.1.5 Hypophosphataemia	1		Risk Ratio (M‐H, Fixed, 95% CI)	Totals not selected
9.1.6 Erythema multiforme	1		Risk Ratio (M‐H, Fixed, 95% CI)	Totals not selected
9.1.7 Periorbital oedema	1		Risk Ratio (M‐H, Fixed, 95% CI)	Totals not selected
9.1.8 Pruritus	1		Risk Ratio (M‐H, Fixed, 95% CI)	Totals not selected
9.1.9 Other AE	1		Risk Ratio (M‐H, Fixed, 95% CI)	Totals not selected